Considering that IGFBP2 is a hepatokine, which shows strong effects on the regulation of lipid metabolism, we estimated the degree of hepatic steatosis in patients with MASLD using CAP value from FibroScan and conducted a correlation analysis to investigate whether the serum level of IGFBP2 is associated with the degree of hepatic steatosis in patients with MASLD. Here, IGFBP2 is linked to fatty liver disease.